Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Biofrontera Inc

Healthcare US BFRI

0.9855USD
-0.0445(4.32%)

Last update at 2026-06-03T20:00:00Z

Day Range

0.971.04
LowHigh

52 Week Range

0.541.19
LowHigh

Fundamentals

  • Previous Close 1.03
  • Market Cap12.70M
  • Volume144519
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-11.21000M
  • Revenue TTM41.70M
  • Revenue Per Share TTM4.10
  • Gross Profit TTM 30.74M
  • Diluted EPS TTM-1.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.51100M -17.73700M -20.11700M -0.60800M -37.65700M
Minority interest - - - - -
Net income -10.53600M -17.75900M -20.13100M -0.64000M -37.71300M
Selling general administrative 38.37M 33.84M 37.70M 35.87M 37.21M
Selling and marketing expenses - - 1.43M 0.73M 0.70M
Gross profit 31.59M 18.70M 16.63M 13.49M 11.36M
Reconciled depreciation 0.87M 1.15M 1.55M 1.17M 0.54M
Ebit -11.34800M -15.59000M -19.51700M -22.38100M -25.85100M
Ebitda -10.48000M -14.44100M -18.45300M -21.17600M -25.16200M
Depreciation and amortization 0.87M 1.15M 1.06M 1.21M 0.69M
Non operating income net other - - - - -
Operating income -11.34800M -17.21000M -22.67700M -22.38100M -25.85100M
Other operating expenses 53.05M 54.53M 56.75M 51.05M 49.95M
Interest expense 0.45M 2.11M 0.60M 0.20M 0.34M
Tax provision 0.03M 0.02M 0.02M 0.03M 0.06M
Interest income - 0.07M 0.17M 0.17M 0.02M
Net interest income -0.45200M -2.07600M -0.29100M -0.19500M -0.34400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.03M 0.02M 0.01M 0.03M 0.06M
Total revenue 41.70M 37.30M 34.07M 28.67M 24.10M
Total operating expenses 42.94M 35.92M 39.30M 35.87M 37.21M
Cost of revenue 10.11M 18.61M 17.44M 15.19M 12.74M
Total other income expense net 0.84M -0.52700M 2.56M 21.77M -11.80600M
Discontinued operations - - - - -
Net income from continuing ops -10.53600M -17.75900M -26.44200M -0.64000M -37.71300M
Net income applicable to common shares - - - -0.64000M -37.71300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 28.56M 22.10M 27.93M 50.88M 53.22M
Intangible assets 2.65M 0.04M 2.63M 3.03M 3.45M
Earning assets - - - - -
Other current assets 2.97M 2.83M 5.58M 0.81M 4.99M
Total liab 18.08M 17.67M 23.14M 27.00M 41.88M
Total stockholder equity 10.48M 4.43M 4.79M 23.88M 11.34M
Deferred long term liab - - - - -
Other current liab 4.90M 9.62M 4.49M 12.18M 3.24M
Common stock 0.01M 0.00900M 0.00200M 0.03M 0.02M
Capital stock 0.01M 0.00900M 0.00200M 0.03M 0.02M
Retained earnings -127.94500M -117.40900M -99.65000M -79.51800M -78.87900M
Other liab - - - 5.26M 28.05M
Good will - - - - -
Other assets - - 0.00000M 3.13M 3.08M
Cash 6.39M 5.91M 1.34M 17.21M 24.55M
Cash and equivalents - - - - -
Total current liabilities 11.89M 12.02M 18.09M 20.89M 13.84M
Current deferred revenue - - - 6.94M 3.24M
Net debt -0.23100M -0.98300M 4.06M -15.86200M -24.54500M
Short term debt 0.33M 0.55M 4.59M 0.50M 6.69M
Short long term debt - - 3.90M - -
Short long term debt total 6.16M 4.92M 5.40M 1.35M -
Other stockholder equity 138.41M 121.83M 104.44M 103.37M 90.20M
Property plant equipment - - - 1.58M 0.27M
Total current assets 18.08M 20.70M 23.07M 43.14M 46.42M
Long term investments - - - - -
Net tangible assets - - - 20.85M 7.89M
Short term investments 0.00900M 0.00700M 0.08M 10.55M -
Net receivables 7.29M 5.32M 5.16M 7.41M 12.43M
Long term debt 4.59M 4.10M - - -
Inventory 1.43M 6.65M 10.91M 7.17M 4.46M
Accounts payable 6.67M 1.86M 9.01M 1.28M 0.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.89M 0.38M 0.28M 3.13M 3.08M
Deferred long term asset charges - - - - -
Non current assets total 10.48M 1.40M 4.86M 7.74M 6.80M
Capital lease obligations 1.57M 0.82M 1.50M 1.35M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M -0.00300M -1.54000M -5.15600M -0.01100M
Change to liabilities - - - 0.91M -0.77300M
Total cashflows from investing activities 3.00M -0.00300M 0.62M -5.15600M -0.01100M
Net borrowings 0.00000M -0.26500M 3.90M - -
Total cash from financing activities 10.85M 14.84M 8.41M 14.02M 43.19M
Change to operating activities - - - 4.76M -2.71200M
Net income -10.53600M -17.75900M -20.13100M -0.64000M -37.71300M
Change in cash 0.49M 4.56M -15.86500M -7.33400M 16.46M
Begin period cash flow 6.11M 1.54M 17.41M 24.74M 8.28M
End period cash flow 6.59M 6.11M 1.54M 17.41M 24.74M
Total cash from operating activities -13.36100M -10.27000M -24.89500M -16.19900M -26.71500M
Issuance of capital stock 10.85M 7.66M 4.51M 9.39M 29.94M
Depreciation 0.14M 1.15M 1.06M 1.17M 0.54M
Other cashflows from investing activities 3.00M -0.05000M - - -
Dividends paid - - - - -
Change to inventory 1.45M 4.23M -3.75000M -2.81000M 2.59M
Change to account receivables -1.90700M -0.31300M 4.93M -0.07000M -0.61200M
Sale purchase of stock - - - - -
Other cashflows from financing activities -10.85000M 15.10M 3.90M 4.63M 13.25M
Change to netincome - - - -19.51900M 11.96M
Capital expenditures 0.00200M 0.06M 0.00500M 0.04M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.48400M 6.21M -4.39400M 2.79M -1.50500M
Stock based compensation 0.95M 1.02M 1.04M 1.85M 0.13M
Other non cash items -0.43000M -0.89100M -2.47900M -21.37100M -1.04400M
Free cash flow -13.36300M -10.33000M -24.90000M -16.23700M -26.72600M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BFRI
Biofrontera Inc		 -0.0445 4.32% 0.99 - 13.64 0.30 1.21 0.30 -0.792
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera Inc

660 Main Street, Woburn, MA, United States, 01801

Key Executives

Name Title Year Born
Dr. Hermann Lubbert Ph.D. Exec. Chairman & Pres 1956
Ms. Erica L. Monaco CPA CEO, COO, Treasurer & Sec. 1985
Mr. Eugene Fredrick Leffler III Chief Financial Officer 1984
Ms. Erica F. Gates CPA, M.B.A. Sr. Director of Fin. & Principal Accounting Officer NA
Ms. Alycia Torres VP of Admin. NA
Mr. Daniel Hakansson J.D. Gen. Counsel & Head of Compliance NA
Mr. Mark Baldyga Head of Sales & Marketing NA
Mr. Jeff Holm Head of Professional Relations & Commercial Devel. NA
Dr. Hermann Luebbert Ph.D. CEO, President & Executive Chairman 1956
Mr. Eugene Frederick Leffler III Chief Financial Officer 1985

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.